Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
39.6 USD | +3.33% | +3.93% | +37.34% |
May. 09 | Wedbush Raises Price Target on Revolution Medicines to $46 From $42, Maintains Outperform Rating | MT |
May. 08 | Revolution Medicines Q1 Net Loss Narrows | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+37.34% | 6.32B | |
+45.68% | 54.63B | |
-6.62% | 39.92B | |
+37.07% | 38.82B | |
+13.40% | 26.86B | |
-11.17% | 26.22B | |
-21.72% | 18.78B | |
+25.72% | 12.21B | |
+0.61% | 12.16B | |
+25.65% | 11.94B |
- Stock Market
- Equities
- RVMD Stock
- News Revolution Medicines, Inc.
- JPMorgan Upgrades Revolution Medicines to Overweight From Neutral, Boosts Price Target to $38 From $32